SimplePractice vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
All-in-one practice management platform for 185,000+ therapists, counselors, social workers, and wellness practitioners; Santa Monica-based;
About
SimplePractice is a Santa Monica-based practice management software company serving independent therapists, counselors, social workers, nutritionists, and other health and wellness practitioners. The platform provides scheduling, client intake forms, HIPAA-compliant telehealth video sessions, insurance billing, payment processing, progress notes, and client messaging in a unified system designed specifically for solo and small group private practices. SimplePractice handles the administrative burden of running a private practice — eligibility verification, superbills, ERA processing — enabling clinicians to spend more time with clients and less time on paperwork. The company serves over 185,000 practitioners across the United States and has become the dominant practice management platform in the mental health private practice segment. Founded in 2012, SimplePractice raised over $50M from investors including Susquehanna Growth Equity and has grown organically through referrals within the therapist community. It competes with TherapyNotes, TheraNest, and Therapy Brands in the mental health software market.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.